Similar articles

• Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

  Cremolini C, Loupakis F, Ruzzo A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, Falcone A. Cremolini C, et al. J Clin Oncol. 2010 Apr 10;28(11):e173-4; author reply e175-6. doi: 10.1200/JCO.2009.26.6148. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177018 No abstract available.
• KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

  de Reyniès A, Boige V, Milano G, Faivre J, Laurent-Puig P. de Reyniès A, et al. J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186. J Clin Oncol. 2008. PMID: 18445856 No abstract available.
• KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer.

  [No authors listed] [No authors listed] Technol Eval Cent Assess Program Exec Summ. 2009 Jan;23(6):1-3. Technol Eval Cent Assess Program Exec Summ. 2009. PMID: 19297803 No abstract available.
• First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.

  Cercek A, Saltz LB. Cercek A, et al. Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S47-51. doi: 10.3816/CCC.2008.s.007. Clin Colorectal Cancer. 2008. PMID: 19064406 Review.
• Molecular mechanisms and targeting of colorectal cancer.

  Vanhoefer U. Vanhoefer U. Semin Oncol. 2005 Dec;32(6 Suppl 8):7-10. doi: 10.1053/j.seminoncol.2005.07.018. Semin Oncol. 2005. PMID: 16360005 Review.